Literature DB >> 22331483

Increased diagnosis and detection rates of carcinoma in situ of the breast.

J A Glover1, F J Bannon, C M Hughes, M M Cantwell, H Comber, A Gavin, S Deady, L J Murray.   

Abstract

The purpose of this study was to identify trends in the diagnosis of carcinoma in situ (CIS) of the breast in the United Kingdom (UK) and the Republic of Ireland (ROI) and to examine the impact of mammography. Data on cases of newly diagnosed CIS of the breast and mode of detection (screen detected or not) were obtained, where available, from regional cancer registries between 1990 and 2007. Age-standardised diagnosis rates for the UK and the ROI, and regional screen detected diagnosis rates were compared by calculating the annual percentage change (APC) over time. The APC of the diagnosis rate amongst women aged 50-64 years (original screening age group) showed a significant 5.9% increase in the UK (1990-2007) and 11.5% increase in the ROI (1994-2007). The rate of diagnosis (50-64 years) stabilized in the UK between 2005 and 2007 and was substantially higher than in other western populations with national screening programmes. The APC of the diagnosis rate amongst those aged 65-69 years showed a significant 12.4% increase in the UK (1990-2007) and 10.3% increase in the ROI (1994-2007). amongst women aged 50-74 years in the UK, approximately 4,300 cases of CIS (≈90% ductal carcinoma in situ) were diagnosed in 2007. Our analyses have shown that screen detected CIS contributed primarily to the increase in diagnosis of CIS of the breast. The high diagnosis rate of screen detected CIS of the breast underlines the need for further research into lesion and patient characteristics that are related to progression of CIS to invasive disease to better target treatment.

Entities:  

Mesh:

Year:  2012        PMID: 22331483     DOI: 10.1007/s10549-012-1975-y

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  4 in total

1.  Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up.

Authors:  Melinda E Sanders; Peggy A Schuyler; Jean F Simpson; David L Page; William D Dupont
Journal:  Mod Pathol       Date:  2014-12-12       Impact factor: 7.842

Review 2.  A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.

Authors:  Mieke R Van Bockstal; Marie C Agahozo; Linetta B Koppert; Carolien H M van Deurzen
Journal:  Int J Cancer       Date:  2019-05-08       Impact factor: 7.396

3.  Type of Recurrence, Cause of Death and Second Neoplasms among 737 Patients with Ductal Carcinoma In Situ of the Breast-15-Year Follow-Up.

Authors:  Anna Niwińska; Michał Kunkiel
Journal:  Cancers (Basel)       Date:  2022-01-28       Impact factor: 6.639

4.  Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study.

Authors:  Taghipour Zahir Shokouh; Aalipour Ezatollah; Poorya Barand
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.